manholdingbacktime
1 April 2013AmericasGabriel Di Blasi

Generic battles: pay-for-delay in Brazil

So-called ‘pay-for-delay’ agreements, also known as reverse payment agreements, are settlements executed between pharmaceutical industries in which a holder of an expired or soon-to-expire patented drug pays its competitor in order to prevent it from producing and selling a corresponding generic drug for a certain period of time.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
23 April 2026   The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.
Americas
23 April 2026   Plaintiff alleges that a $6 billion rival probed its records system via a long-term customer, using confidential information to develop its product in the behavioural health tech space.
Americas
22 April 2026   Decision underscores a growing deference to parallel rulings and tighter control over duplicate patent challenges.